|
Brachytherapy And High Dose EBRT-
Equivalent Results
(February 2007)
[in
low- and intermediate-risk patients]: (Abstract #38, 2006 ASCO
Prostate Cancer Symposium). Drs. Shipley, Zietman, et al (MGH) reported an
analysis of well-matched cases in two cohorts each of 132 patients (T1-2,
PSA < 15); one treated with brachytherapy and the other with EBRT
(79.2 Gy). Case matching was based on T-stage (T1, 75%; T2 25%); Gleason
score ( GS 6, 85%; GS 7, 13%; GS 8-10, 2%; PSA (median PSA, 6.1 for EBRT;
5.5 for BT); and age. Results: 5 year overall survival and distant
metastases-free survival was 98% for both groups; freedom from biochemical
failure at 5 years - EBRT, 88%; BT, 90%. «
Back to Article List |
